
OBJECTIVE:To determine whether adults with type 2 diabetes mellitus (T2DM) using cetirizine, ibuprofen, or prednisone have a reduced incidence of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). DESIGN:Retrospective propensity score-matched cohort study. PARTICIPANTS:Adults with T2DM and documented eye-care in the TriNetX US Collaborative Network who had two documented uses of cetirizine, ibuprofen, prednisone, fenofibrate, or gabapentin between January 1, 2005, and March 1, 2025. METHODS:Each drug cohort was 1:1 propensity score-matched on 44 covariates against non-users; fenofibrate served as a positive control, and gabapentin served as both a negative control and an active comparator. Residual confounding was assessed using eight ophthalmic negative-control outcomes (NCOs) and E-values. Nine sensitivity analyses tested comparison to users of gabapentin, alternative outcome windows, a new-user design, glycemic strata, matching for drug indication, and exposure duration. MAIN OUTCOME MEASURES:Incident DME and PDR within 3 years of the index date. RESULTS:Matched-pair counts ranged from 18,762 to 86,846. Cetirizine was associated with reduced DME (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.51-0.74) and PDR (HR, 0.59; 95% CI, 0.46-0.77); ibuprofen with reduced DME (HR, 0.63; 95% CI, 0.56-0.69) and PDR (HR, 0.48; 95% CI, 0.41-0.56); and prednisone with reduced DME (HR, 0.46; 95% CI, 0.41-0.52) and PDR (HR, 0.36; 95% CI, 0.30-0.43). Fenofibrate showed associations of similar magnitude (DME HR, 0.57; 95% CI, 0.48-0.68; PDR HR, 0.59; 95% CI, 0.45-0.77); gabapentin showed no association (DME HR, 0.95; 95% CI, 0.88-1.02; PDR HR, 1.04; 95% CI, 0.93-1.15). Point E-values for the investigational drugs ranged from 2.57 to 4.97 (lower 95% CI bound, 1.93 to 4.06). The NCO panel was near null for cetirizine and ibuprofen and showed mild protective bias for prednisone and fenofibrate. Findings persisted across the nine sensitivity analyses. CONCLUSIONS:Cetirizine, ibuprofen, and prednisone were associated with reduced incidence of DME and PDR in adults with T2DM, with effect sizes comparable to those of the fenofibrate positive control. These findings support prospective evaluation of anti-inflammatory medications for the prevention of vision-threatening diabetic retinopathy.
Among 4,578 adults with DR, RVO, or eAMD in All of Us, minority participants reported more transportation, affordability, childcare, and discriminatory care experiences; disparities were greatest in DR, supporting equity-focused redesign of retinal care delivery.
PURPOSE:To evaluate the primary efficacy and safety of satralizumab, an anti-interleukin-6 receptor antibody, in patients with thyroid eye disease (TED). DESIGN:SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828) are identically designed, 72-week, double-masked, placebo-controlled, multicenter, 2-stage randomization phase 3 trials. PARTICIPANTS:Aged ≥18 years with active, moderate to severe TED (Clinical Activity Score [CAS] ≥3 for ≤12 months) or inactive TED (CAS <3 for ≥6 months). METHODS:Participants (SatraGO-1: N = 131; SatraGO-2: N = 127) were randomized 1:1 to receive loading doses of subcutaneous satralizumab or placebo at weeks 0, 2, and 4, followed by every-4-week dosing through week 20 (part I). MAIN OUTCOME MEASURES:The primary endpoint was the proportion of participants with active TED who achieved a proptosis response (≥2-mm reduction from baseline) at week 24. Secondary endpoints included the proportion of participants with a ≥2-point CAS reduction, disease inactivation (CAS of 0 or 1), and an ≥1-grade diplopia reduction at week 24. Efficacy outcomes were also reported for the combined active and inactive TED population. Safety was assessed in all participants exposed to study treatment. RESULTS:In participants with active TED, the satralizumab arm of both trials consistently showed an increased proportion achieving a proptosis response (SatraGO-1: 49.0% vs. 31.2%, P = 0.0715; SatraGO-2: 52.9% vs. 23.4%, P = 0.0011), CAS reduction (SatraGO-1: 78.0% vs. 54.9%, P = 0.0120; SatraGO-2: 89.6% vs. 63.3%, P = 0.0009), CAS of 0 or 1 (SatraGO-1: 68.0% vs. 45.1%, P = 0.0146; SatraGO-2: 68.8% vs. 40.8%, P = 0.0042), and diplopia reduction (SatraGO-1: 44.4% vs. 34.4%, P = 0.3371; SatraGO-2: 60.7% vs. 25.8%, P = 0.0044) vs. placebo, although not all comparisons reached statistical significance. Similar clinical benefits were observed in the combined active and inactive TED population. Satralizumab was well tolerated, with low rates of serious adverse events, treatment discontinuations, and infections, and no serious infections. CONCLUSIONS:Satralizumab demonstrated clinically meaningful improvements in proptosis, CAS, and diplopia, and had a favorable safety profile in participants with TED. Interleukin-6 pathway inhibition with subcutaneous satralizumab represents an efficacious and well-tolerated treatment option for patients with TED.